<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>772</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15153475</PubmedId>
            <Abstract>We examined the role of reduction in the presentation of two H2-E(d)-restricted epitopes (site 1 epitope (S1) and site 3 epitope (S3)) occupying distinct domains of the influenza hemagglutinin major subunit that contains four intrachain disulfide bonds and is connected to the virion by one interchain bond. S3 is situated within the stalk region that unfolds in response to mild acidification, and loads onto recycling H2-E(d) in the early endosome, while S1, located in the structurally constrained globular domain, loads onto nascent H2-E(d) in the late endosome. Predicting dependence upon reduction for either epitope seemed plausible but the results from several approaches were clear: presentation of S1 but not S3 is reduction dependent. Surprisingly, IFN-gamma-inducible lysosomal thiol reductase (GILT), the only reductase thus far known to be involved in MHC class II-restricted processing, is not necessary for the generation of S1. However, GILT is necessary for presentation of either epitope when the virus is pretreated with a reducible cross-linker. The results suggest that unfolding of the Ag, perhaps a prerequisite for proteolytic processing in many cases, proceeds either spontaneously in the early endosome or via reduction in a later endosome. They further imply mechanisms for GILT-independent reduction in the late endosome, with GILT perhaps being reserved for more intractable Ags.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>6607-14</ArticlePages>
            <ArticleTitle>Differential requirements for endosomal reduction in the presentation of two H2-E(d)-restricted epitopes from influenza hemagglutinin.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Sinnathamby</LastName>
                    <ForeName>Gomathinayagam</ForeName>
                </Author>
                <Author>
                    <LastName>Maric</LastName>
                    <ForeName>Maja</ForeName>
                </Author>
                <Author>
                    <LastName>Cresswell</LastName>
                    <ForeName>Peter</ForeName>
                </Author>
                <Author>
                    <LastName>Eisenlohr</LastName>
                    <ForeName>Laurence C</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Microbiology and Immunology, Kimmel Cancer Institute, Thomas Jefferson University, Philadelphia, PA 19107, USA.</Affiliations>
            <ArticleChemicalList>Epitopes;Hemagglutinin Glycoproteins, Influenza Virus;Histocompatibility Antigens Class II;Protein Subunits;Oxidoreductases;Ifi30 protein, mouse</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Antigen Presentation; Cricetinae; Endosomes(physiology); Epitopes; Hemagglutinin Glycoproteins, Influenza Virus(chemistry; immunology); Histocompatibility Antigens Class II(metabolism); Mice; Oxidoreductases(physiology); Protein Subunits</ArticleMeshHeadingsList>
            <Journal>
                <Volume>172</Volume>
                <Issue>11</Issue>
                <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
                <Issn>0022-1767</Issn>
                <MedlineTa>J Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>S1</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SVSSFERFEIFPK</LinearSequence>
                        <StartingPosition>107</StartingPosition>
                        <EndingPosition>119</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>YP_163735.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>211044</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 6608</LocationOfData>
                <EpitopeId>62335</EpitopeId>
                <ReferenceStartingPosition>107</ReferenceStartingPosition>
                <ReferenceEndingPosition>119</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>This peptide is located in the globular domain of HA, requiring H2-M for loading into MHC II. Intrasulfide bonds in this domain indicated the requirement of reduction for APC presentation of this epitope. This is confirmed in the paper, but it shows no involvement of GILT reductase.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 2 and 3</LocationOfData>
                        <TCellId>8075</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>The generation of epitope specific T cell hybridomas that express β-galactosidase upon Ag-driven stimulation has been described previously (Rajagopal, D., M. Tewari, N. Yeh, and L. C. Eisenlohr. 2001. In The World Congress on Options for the Control of Influenza, Vol. IV. A. Osterhaus,N. Cox, and A. Hampson, eds. Elsevier Science, Crete, p. 319.).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>10026</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>116</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>PR8</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>187</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Hamster ovary cell line are used as APC. This line is deficient in presenting Ag with S-S bonds due to low intracellular glutathione levels. They were transfected with H2-Ed and pulsed with source virus (PR8), or PR8 crosslinked with a reducible agent, or with S1 peptide.This negative result shows the need of an intact reducing capacity in APCs for presentation of S1 from intact or cross-linked PR8. Presentation of S1 peptide is normal, implying processing is affected with low reducing capability.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 5B, 6, and 7</LocationOfData>
                        <TCellId>8076</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>The generation of epitope specific T cell hybridomas that express β-galactosidase upon Ag-driven stimulation has been described previously (Rajagopal, D., M. Tewari, N. Yeh, and L. C. Eisenlohr. 2001. In The World Congress on Options for the Control of Influenza, Vol. IV. A. Osterhaus,N. Cox, and A. Hampson, eds. Elsevier Science, Crete, p. 319.).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>Fibroblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>10090</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>116</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>PR8</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>187</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Mouse fibroblast cell line is used as APC. They were transfected with H2-Ed and iRNA for GILT, and pulsed with source virus (PR8), or PR8 crosslinked with a reducible agent. GILT -/- primary fibroblast were also used (Fig 7), to confirm iRNA results. These results show that presentation of S1 is independent of GILT activity unless the virus is crosslinked with a reducible agent.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>S3</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>CPKYVRSAKLRM</LinearSequence>
                        <StartingPosition>303</StartingPosition>
                        <EndingPosition>314</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>YP_163735.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>211044</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 6608</LocationOfData>
                <EpitopeId>6802</EpitopeId>
                <ReferenceStartingPosition>302</ReferenceStartingPosition>
                <ReferenceEndingPosition>313</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>This peptide is located in the stalk domain of HA, and doesn't require H2-M for loading into MHC II. Requirement of sulfide bond reduction for APC presentation of this peptide was unclear. This paper shows it is not required as glutathione and GILT reductase deficient cells effectively present this epitope from source virus. If the virus is crosslinked with a reducible agent, then presentation is GILT dependent.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 5B, 6, and 7</LocationOfData>
                        <TCellId>8079</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>The generation of epitope specific T cell hybridomas that express β-galactosidase upon Ag-driven stimulation has been described previously (Rajagopal, D., M. Tewari, N. Yeh, and L. C. Eisenlohr. 2001. In The World Congress on Options for the Control of Influenza, Vol. IV. A. Osterhaus,N. Cox, and A. Hampson, eds. Elsevier Science, Crete, p. 319.).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>Fibroblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>10090</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>116</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>PR8</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>187</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Mouse fibroblast cell line is used as APC. They were transfected with H2-Ed and iRNA for GILT, and pulsed with source virus (PR8), or PR8 crosslinked with a reducible agent. GILT -/- primary fibroblast were also used (Fig 7), to confirm iRNA results. These result show that the presentation of S3 is independent of GILT activity unless the virus is crosslinked with a reducible agent.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 2 and 3</LocationOfData>
                        <TCellId>8078</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>The generation of epitope specific T cell hybridomas that express β-galactosidase upon Ag-driven stimulation has been described previously (Rajagopal, D., M. Tewari, N. Yeh, and L. C. Eisenlohr. 2001. In The World Congress on Options for the Control of Influenza, Vol. IV. A. Osterhaus,N. Cox, and A. Hampson, eds. Elsevier Science, Crete, p. 319.).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>10026</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>116</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>PR8</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>187</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Hamster ovary cell line are used as APC. This line is deficient in presenting Ag with S-S bonds due to low intracellular glutathione levels. They were transfected with H2-Ed and pulsed with source virus (PR8), or PR8 crosslinked with a reducible agent, or with S3 peptide. These results show APCs present S3 from intact PR8 even in non-reducing environments, but presentation from cross-linked PR8 is impaired in that condition.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

